A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma

被引：0

作者：

Sun Jin Sym

Dae Ho Lee

Hye Jin Kang

Seung Hyun Nam

Ho Young Kim

Seok Jin Kim

Hyeon Seok Eom

Won Seog Kim

Cheolwon Suh

机构：

[1] Asan Medical Center,Department of Internal Medicine

[2] University of Ulsan College of Medicine,Department of Medicine

[3] Korea Institute of Radiological and Medical Sciences,Department of Internal Medicine

[4] Seoul Veterans Hospital,Department of Internal Medicine, Sacred Heart Hospital

[5] College of Medicine,Department of Internal Medicine

[6] Hallym University,Hematology–Oncology Clinic, Research Institute and Hospital

[7] College of Medicine,Department of Medicine, Samsung Medical Center

[8] Korea University,Department of Internal Medicine

[9] National Cancer Center,undefined

[10] School of Medicine,undefined

[11] Sungkyunkwan University,undefined

[12] Gachon University Gil Hospital,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2009年 / 64卷

关键词：

Oxaliplatin; Lymphoma; Salvage therapy; Chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：27 / 33

页数：6

共 50 条

[1] A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma
Sym, Sun Jin
Lee, Dae Ho
Kang, Hye Jin
Nam, Seung Hyun
Kim, Ho Young
Kim, Seok Jin
Eom, Hyeon Seok
Kim, Won Seog
Suh, Cheolwon
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) : 27 - 33
[2] A Multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory/relapsed aggressive non-Hodgkin's lymphoma
Sym, Sun Jin
Kang, Hye Jin
Nam, Seung-Hyun
Kim, Hoyoung
Kim, Seok Jin
Eom, Hyeon Seok
Kim, Won Seog
Suh, Cheolwon
BLOOD, 2007, 110 (11) : 1010A - 1010A
[3] A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with refractory/relapsed aggressive non-Hodgkins lymphoma: Preliminary results
Sym, S. J.
Kang, H. J.
Nam, S. H.
Kim, H. Y.
Kim, S. J.
Eom, H. S.
Kim, W. S.
Suh, C. W.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 268 - 269
[4] A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin’s lymphoma
Young-Woong Won
Hyewon Lee
Hyeon-Seok Eom
Jin Seok Kim
Cheolwon Suh
Dok Hyun Yoon
Jung Yong Hong
Hye Jin Kang
Jae Hoon Lee
Won Seog Kim
Seok Jin Kim
Won-Sik Lee
Myung Hee Chang
Young Rok Do
Jun Ho Yi
Inho Kim
Jong-Ho Won
Kyoungha Kim
Sung Yong Oh
Jae-Cheol Jo
Annals of Hematology, 2020, 99 : 255 - 264
[5] A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma
Won, Young-Woong
Lee, Hyewon
Eom, Hyeon-Seok
Kim, Jin Seok
Suh, Cheolwon
Yoon, Dok Hyun
Hong, Jung Yong
Kang, Hye Jin
Lee, Jae Hoon
Kim, Won Seog
Kim, Seok Jin
Lee, Won-Sik
Chang, Myung Hee
Do, Young Rok
Yi, Jun Ho
Kim, Inho
Won, Jong-Ho
Kim, Kyoungha
Oh, Sung Yong
Jo, Jae-Cheol
ANNALS OF HEMATOLOGY, 2020, 99 (02) : 255 - 264
[6] High-dose ifosfamide and etoposide infusion plus methylprednisolone for refractory or relapsed aggressive non-Hodgkin's lymphoma
Salar, A
Martino, R
Altés, A
Sureda, A
Brunet, S
Sierra, J
HAEMATOLOGICA, 2000, 85 (02) : 217 - 219
[7] Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma
Machover, D
Delmas-Marsalet, B
Misra, SC
Gumus, Y
Goldschmidt, E
Schilf, A
Frénoy, N
Emile, JF
Debuire, B
Guettier, C
Farrokhi, P
Boulefdaoui, B
Norol, F
Parquet, N
Ulusakarya, A
Jasmin, C
ANNALS OF ONCOLOGY, 2001, 12 (10) : 1439 - 1443
[8] Cologne high-dose sequential chemotherapy in relapsed and refractory aggressive non-Hodgkin's lymphoma results of multicenter phase II study
Josting, A
Sieniawski, M
Staak, J
Diehl, V
Engert, A
ANNALS OF ONCOLOGY, 2005, 16 : 183 - 183
[9] A phase II trial of dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab as salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma.
Mey, UJM
Strehl, JW
Orlopp, KS
Flieger, D
Birkmann, J
Ho, A
Kaiser, U
Neubauer, A
Glasmacher, AG
Schmidt-Wolf, IGH
BLOOD, 2004, 104 (11) : 238B - 238B
[10] Dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab as salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma: Updated results of a multicenter phase II trial.
Mey, UJM
Flieger, D
Birkmann, J
Neubauer, A
Ho, AD
Kaiser, U
Wilhelm, M
Haarmann, G
Hahn, C
Strehl, JW
Glasmacher, AG
Schmidt-Wolf, IGH
BLOOD, 2003, 102 (11) : 300B - 301B

← 1 2 3 4 5 →